Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:15:00 18/06/2025 BST			After hours 22:08:09
108.00 ^USD	0.00%		107.30	-0.64%

09:49pm	US FDA approves Gilead's twice-yearly injection for HIV prevention	RE
08:39pm	Gilead Sciences' Twice-Yearly HIV-Prevention Drug Gets FDA Approval	DJ

Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76

Published on 15/04/2024 at 12:24, updated on 15/04/2024 at 12:44

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Gilead Sciences, Inc.

US FDA approves Gilead's twice-yearly injection for HIV prevention	09:49pm	RE
Gilead Sciences' Twice-Yearly HIV-Prevention Drug Gets FDA Approval	08:39pm	DJ
Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval	08:25pm	MT
US FDA approves Gilead's twice-yearly injection for HIV prevention	07:37pm	RE
FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention	07:24pm	RE
US FDA approves Gilead's twice-yearly injection for HIV prevention	07:17pm	RE
Xponential Fitness, Inc. Appoints Lily Yang to its Board of Directors, Effective June 16, 2025	06-17	CI
Gilead Sciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11:20 AM	06-13
Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says	06-11	MT
RBC Capital Raises Price Target on Gilead Sciences to $95 From $92, Keeps Sector Perform Rating	06-11	MT
US FDA pauses Gilead trials testing experimental HIV pill combination	06-10	RE
US FDA pauses Gilead trials testing experimental HIV pill combination	06-10	RE
Gilead : FDA Places Clinical Hold on HIV Treatment Trials of GS-1720, GS-4182	06-10	DJ
Gilead Says FDA Puts Clinical Hold on HIV Combination Trials	06-10	MT
Gilead Says FDA Placed Clinical Hold On HIV Treatment Trials Of GS-1720 And/Or GS-4182	06-10	RE
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination	06-10	RE
Gilead Sciences, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 11:05 AM	06-04
Gilead Sciences Insider Sold Shares Worth $1,104,193, According to a Recent SEC Filing	06-03	MT
DBS Bank Adjusts Price Target on Gilead Sciences to $140 From $125, Maintains Buy Rating	06-02	MT
Merck, Gilead Combination Reduces Disease-Progression Risk of Breast Cancer in Phase 3 Study	06-02	MT
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial	06-02	RE
Gilead's CAR-T cell therapy shows promise in deadly brain cancer	06-01	RE
Merck Says Keytruda® Plus Trodelvy® Reduced Risk Of Disease Progression Or Death By 35% Versus Keytruda Plus Chemotherapy In First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer	05-31	RE
Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer	05-31	CI
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty	05-30	RE

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).

Employees

17,600

Sector

Pharmaceuticals

Calendar

08-04 - Q2 2025 Earnings Release (Projected)

More about the company